In high-risk patients, combination of antiinflammatory procedures during cardiopulmonary bypass can reduce incidences of inflammation and oxidative stress

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 1, 2007, Pages 39-45

  Goudeau, Jean Jacques ^a   Clermont, Gaëlle ^b   Guillery, Olivier ^a   Lemaire Ewing, Stéphanie ^a   Musat, Andy ^a   Vernet, Magali ^a   Vergely, Catherine ^b   Guiguet, Michel ^a   Rochette, Luc ^b   Girard, Claude ^a,b  

^a HÔPITAL DU BOCAGE   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Aprotinin; Cardiopulmonary bypass; Free radicals; Inflammation; Interleukin 6

Indexed keywords

APROTININ; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARDIOPLEGIC AGENT; CREATINE KINASE MB; FREE RADICAL; HEPARIN; INTERLEUKIN 6; LACTIC ACID; PROTAMINE; ST THOMAS HOSPITAL SOLUTION; TROPONIN I;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL MEDICINE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MEGADOSE; ELECTRON SPIN RESONANCE; EVALUATION; FEMALE; HEART HEMODYNAMICS; HEART SURGERY; HEMOFILTRATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LENGTH OF STAY; MALE; OXIDATIVE STRESS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SPECTROSCOPY; SPIN TRAPPING; SYSTEMIC CIRCULATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ACUTE-PHASE REACTION; AGED; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INCIDENCE; INFLAMMATION; MALE; OXIDATIVE STRESS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 33846599337     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802c0cd0     Document Type: Article

References (28)

1. Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg. 1991;51:529-531.
2. a anaphylatoxins. N Engl J Med. 1981;304:497-503.
3. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardio Thorac Vasc Anesth. 1997;11:355-366.
4. Faymonville ME, Pincemail J, Duchateau J, et al. Myeloperoxidase and elastase as markers of leucocytes activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg. 1991;102:309-317.
5. Prasad K, Kalra J, Bahradwaj B, et al. Increased oxygen free radical activity in patients on cardiopulmonary bypass undergoing aortocoronary bypass surgery. Am Heart J. 1992;123:37-45.
6. Clermont G, Vergely-Vandriesse C, Jazayeri S, et al. Peripheral free radical activation is the major component involved in oxidative stress related to cardiopulmonary bypass. Anesthesiology. 2002;96:80-87.
7. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation. 1989;79:I3-12.
8. Gatti G, Cardu G, Lusa AM, et al. Predictors of post-operative complications in high-risk octogenarians undergoing cardiac surgery. Ann Thorac Surg. 2002;74:671-677.
9. Rady MY, Ryan T, Starr NJ. Perioperative determinants of morbidity and mortality in elderly patients undergoing cardiac surgery. Crit Care Med. 1998;26:225-235.
10. Laffey JG, Boylan JF, Cheng DCH. The systemic inflammatory response to cardiac surgery Implications for the anesthesiologist. Anesthesiology. 2002;97:215-252.
11. Royston D, Taylor KM, Bidstrup BP, et al. Effects of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289-1291.
12. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940-1947.
13. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact neutrophil and platelet activation systems during simulated extracorporeal circulation. J Thorac Cardiovasc Surg. 1993;106:1-10.
14. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
15. Wan S, LeClerc JL, Antoine M, et al. Heparin coated circuits reduce myocardial injury in heart or heart-lung transplantation: A prospective randomised study. Ann Thorac Surg. 1999;68:1230-1235.
16. Olsson C, Siegbahn A, Halden E, et al. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits. Ann Thorac Surg. 2000;69:743-749.
17. Defraigne JO, Pincemail J, Larbuisson R, et al. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000;69:1084-1091.
18. Journois D, Israel-Biet D, Pouard P, et al. High-volume zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology. 1996;85:965-976.
19. Rubens FD, Nathan H, Labow R, et al. Effects of methylprednisolone and biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg. 2005;79:655-665.
20. Bourbon A, Vionnet M, Leprince P, et al. The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response. Eur J Cardiothorac Surg. 2004;26:932-938.
21. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 1990;4:2860-2867.
22. Maruo N, Norita I, Shirao M, et al. IL-6 increases endothelial permeability in vitro. Endocrinology. 1992;131:710-714.
23. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
24. Kawamura T, Nara N, Kadosaki M, et al. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting pro-inflammatory cytokines production during cardiac surgery. Crit Care Med. 2000;28:2201-2208.
25. Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest Nov. 1999;116:1233-1239.
26. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1-78.
27. Lasocki S, Provenchère S, Benessiano J, et al. Cardiac I-troponin I is an independent proctor of in-hospital death after cardiac surgery. Anesthesiology. 2002;97:405-411.
28. Paraskevaidis IA, Iliodromitis EK, Vlahakos, D et al. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur Heart J. 2005;26:263-270.